Related Experiment Video
Updated: Jun 1, 2025

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
β-Glucuronidase-Responsive Albumin-Binding Prodrug of Colchicine-Site Binders for Selective Cancer Therapy
Alexandra Bordes1, Isabelle Opalinski1, Fabien Thoreau1
1University of Poitiers, UMR CNRS 7285, Institut de Chimie des Milieux et Matériaux de Poitiers (IC2MP)., Equipe Labellisée Ligue Contre le Cancer, 4 rue Michel-Brunet, TSA 51106, 86073, Poitiers cedex 9, France.
Abstract:
The development of novel therapeutic strategies enabling the selective destruction of tumors while sparing healthy tissues is of great interest to improve the efficacy of cancer chemotherapy. In this context, we designed a β-glucuronidase-responsive albumin-binding prodrug programmed to release a potent Isocombretastatin A-4 analog within the tumor microenvironment. When injected at a non-toxic dose in mice bearing orthotopic triple-negative mammary tumors, this prodrug produced a significant anticancer activity, therefore offering a valuable alternative to the systemic administration of the parent drug.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drug Distribution: Tissue Binding
For...
Drug Metabolism: Phase II Reactions
Drug Distribution: Plasma Protein Binding
Drugs for Treatment of Ulcerative Colitis in IBD
Phase II Reactions: Glucuronidation

